AKEBIA THERAPEUTICS, INC. Deferred Tax Liabilities, Intangible Assets
AKEBIA THERAPEUTICS, INC. (AKBA) had Deferred Tax Liabilities, Intangible Assets of $0 as of 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets · last filed 2025-03-13
- 2024-12-31: Deferred Tax Liabilities, Intangible Assets $0.00.
- 2023-12-31: Deferred Tax Liabilities, Intangible Assets $6.87M.
- 2022-12-31: Deferred Tax Liabilities, Intangible Assets $15.98M.
- 2021-12-31: Deferred Tax Liabilities, Intangible Assets $25.60M.
| Period end | Deferred Tax Liabilities, Intangible Assets |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-13 |
| 2023-12-31 | $6.87M 10-K · filed 2025-03-13 |
| 2022-12-31 | $15.98M 10-K · filed 2024-03-14 |
| 2021-12-31 | $25.60M 10-K/A · filed 2023-08-28 |
| 2020-12-31 | $34.18M 10-K · filed 2022-03-01 |
| 2019-12-31 | $75.94M 10-K · filed 2021-02-25 |
| 2018-12-31 | $81.85M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |